Patents by Inventor Janet Elizabeth Codd

Janet Elizabeth Codd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
    Publication number: 20130011447
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Controlled-release nanoparticulate compositions
    Patent number: 8293277
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: October 23, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Glipizide compositions
    Patent number: 8236352
    Abstract: The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: August 7, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: H. William Bosch, Niels P. Ryde, Rajeev A. Jain, Jon Swanson, Robert Hontz, John G. Devane, Kenneth Ian Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
    Publication number: 20120114754
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Inventors: Rajeev A. Jain, Stephen B. RUDDY, Kenneth Iain CUMMING, Maurice Joseph Anthony CLANCY, Janet Elizabeth CODD
  • CONTROLLED RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
    Publication number: 20110300210
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: May 6, 2011
    Publication date: December 8, 2011
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
    Publication number: 20090297619
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: June 11, 2009
    Publication date: December 3, 2009
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Rapidly disintegrating solid oral dosage form
    Publication number: 20090130213
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, or less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 21, 2009
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth lain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Nanoparticulate anticonvulsant and immunosuppressive compositions
    Publication number: 20080248123
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: March 26, 2008
    Publication date: October 9, 2008
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Rapidly disintegrating solid oral dosage form
    Publication number: 20080213371
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: February 11, 2008
    Publication date: September 4, 2008
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth lain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Controlled release nanoparticulate compositions
    Publication number: 20080124393
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 29, 2008
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Rapidly disintegrating solid oral dosage form
    Publication number: 20040057993
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: September 23, 2003
    Publication date: March 25, 2004
    Applicant: Elan Pharma International Limited
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Rapidly disintegrating solid oral dosage form
    Publication number: 20040013613
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: January 15, 2003
    Publication date: January 22, 2004
    Inventors: Rajeev A Jain, Stephen B Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • CONTROLLED-RELEASE NANOPARTICULATE COMPOSITIONS
    Publication number: 20020012675
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: June 22, 1999
    Publication date: January 31, 2002
    Inventors: RAJEEV A. JAIN, JON SWANSON, ROBERT HONTZ, JOHN DEVANE, KENNETH IAIN CUMMING, MAURICE JOSEPH ANTHONY CLANCY, JANET ELIZABETH CODD
  • Rapidly disintegrating solid oral dosage form
    Patent number: 6316029
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: November 13, 2001
    Assignee: Flak Pharma International, Ltd.
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd